July 1 Quick Takes: Cancer metabolism company Faeth raises $47M series A
Plus Cytokinetics prices $450M note deal and updates from NRx and Regard
San Francisco cancer metabolism company Faeth Therapeutics Inc. debuted Thursday with $47 million in series A financing led by S2G Ventures. Also participating were Khosla Ventures and Future Ventures, who co-led the company’s $20 million seed round, and Digitalis, KdT Ventures, AgFunder and Cantos. Faeth is advancing nutrient control regimens to enhance the efficacy of approved therapies; preclinical candidates discovered via its MetabOS machine learning and functional genomics platform; and digital tools to support patients and clinicians. Faeth’s technology is based on research from the labs of Dana-Farber Cancer Institute’s Lew Cantley, Cancer Research UK’s Greg Hannon and Karen Vousden, Memorial Sloan Kettering Cancer Center's Scott Lowe, and Columbia University’s Siddhartha Mukherjee.
Muscle biology company Cytokinetics Inc. (NASDAQ:CYTK) priced an offering of $450 million of 3.50% convertible senior notes due 2027. The South San Francisco muscle function company will repurchase about $116.9 million of 4.00% convertible senior notes due 2026...